Risperidone

What is risperidone?

The treatment of bipolar disorder is complex due to the presence of varying configurations of symptoms in patients. The primary treatments for bipolar disorder are pharmacological, and often involve second generation antipsychotic drugs, such as risperidone. Based on its affinity for dopamine and serotonin receptors, risperidone has been proposed as a treatment for bipolar disorder.

What is the evidence for risperidone as treatment for bipolar disorder?

Symptoms

Moderate quality evidence suggests small to medium-sized effects of greater improvement in acute mania symptoms with risperidone than with placebo, aripiprazole, valporate, lamotrigine, licarbazepine, or topiramate, although there was greater improvement with tamoxefin than with risperidone. Moderate to high quality evidence suggests small to medium-sized effects of greater improvement in depression symptoms and better response to treatment with quetiapine than with risperidone.

Relapses

Moderate quality evidence suggests a small effect of fewer relapses (any) with risperidone than with placebo.

Side effects

Moderate quality evidence suggests more somnolence and all cause treatment discontinuation with risperidone than with placebo. There was also less all-cause discontinuation with topiramate than with risperidone and more switching to mania with quetiapine than with risperidone.

Moderate to low quality evidence suggests greater increases in prolactin levels with risperidone than with lithium or valproate.

April 2019

Last updated at: 5:33 am, 2nd April 2019
To view documentation related to this topic download the files below
Fact Sheet Technical Commentary

NeuRA Libraries

Title Colour Legend:
Green - Topic summary is available.
Orange - Topic summary is being compiled.
Red - Topic summary has no current systematic review available.